N/A N=664 Behavioral Economics Applications to Geriatrics Leveraging EHRs
Prostate Specific Antigen · Asymptomatic Bacteriuria · Type 2 Diabetes Mellitus
Primary: Misuse of Urinalysis or Urine Culture in Older Women — 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16,715 Enhanced, EHR-facilitated Cancer Symptom Control Pragmatic Clinical Trial
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Sleep Disturbance, Pain, Anxiety, Depression, Fatigue (SPADE) Symptom Scores. — 2.09; 1.98; 1.90; 1.81 score on a scale
N/A N=23 Optimizing Cognitive, Environmental, and Neuromotor Stimulation in Traumatic Brain Injury
Traumatic Brain Injury · Dementia Alzheimers · Military Activity
Primary: Change in Executive Functioning as Assessed by the Trail Making Test — -9.2; 24.7 change in seconds — p=.323
Phase 3 N=84 A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Childhood Absence Epilepsy · Juvenile Absence Epilepsy
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 42.2; 55.0 percentage of participants
N/A N=252 French Validation of an Interview Guide to Cancer Announcement : the Psycho Oncology Basic Documentation
Cancer · With Caregiver Support Time · 18 Years and Over
Primary: Reliability of the Questionnaire in Terms of Internal Consistency — 0.87 alpha coefficient
N/A N=111 A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib
Breast Cancer · Adjuvant Therapy · HER2-positive Breast Cancer
Primary: Description of Age — 49.2 years
N/A N=16 Community-Engaged Options to Facilitate Opioid Reduction
Chronic Pain
Primary: Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Rating — 68.3; 64.4 score on a scale — p=<0.001
N/A N=51 SuPRA: Using Wearable Activity Trackers With a New Application to Improve Physical Activity in Knee Osteoarthritis
Joint Diseases · Knee Osteoarthritis
Primary: Daily Number of Minutes in Moderate/Vigorous Physical Activity — 31.0; 71.3; 37.7; 49.4 Minutes per day — p=0.05
Phase 1 N=21 A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BI 836880 Monotherapy and Combination Therapy of BI 836880 and BI754091 — NA; NA milligram
N/A N=145 Safety of Nerivio in Pregnant Women With Migraine
Migraine · Pregnancy Related
Primary: Gestational Age at Delivery — 271; 273 Gestational days — p=0.160
Phase 1 N=300 A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
Healthy Volunteer
Primary: Maximum Observed Serum Concentration (Cmax) of Tocilizumab — 10.5; 10.0 micrograms per milliter (μg/mL)
Phase 1 N=21 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
Glioblastoma · Brain Tumor · GBM
Primary: Maximum Tolerated Dose (MTD) — 100; 300 mg/day Vorinostat
Phase 2 N=518 Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
Pain · Osteo Arthritis Knee · Knee Osteoarthritis
Primary: Least Squares Mean Change From Baseline in WOMAC Pain — -2.77; -2.87; -3.05; -2.26 units on 0-10 point scale
Phase 3 N=318 Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
Chronic Cerebral Ischemia
Primary: Mean Score of Montreal Cognitive Assessment (MoCA) at Visit 5 in Comparison With Reference Score at Visit 0 — 25.72; 23.95; 4.22; 2.17 score on a scale
N/A N=56 Pain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID)
Peripheral Arterial Disease · Intermittent Claudication
Primary: Change in Absolute Claudication Distance (ACD) in Meters From Baseline — -16.8; -6.7; 76.2; -0.9 metres